<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04929236</url>
  </required_header>
  <id_info>
    <org_study_id>NGAM-11</org_study_id>
    <nct_id>NCT04929236</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients</brief_title>
  <official_title>Multicenter, Prospective, Double-Blinded, Parallel Group, Randomized Phase III Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Octapharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Octapharma</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory&#xD;
      Demyelinating Polyradiculoneuropathy (CIDP) Patients&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double-Blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>CIDP Improvement</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Evaluate percentage of patients with CIDP improvement between 2 doses of Panzyga</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CIDP Relapse</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Evaluate percentage of patients with CIDP relapse between 2 doses of Panzyga</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Emergent Adverse Event Occurrence</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Treatment Emergent Adverse Event Occurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to improvement of CIDP</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Time to improvement of CIDP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to relapse of CIDP</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Time to relapse of CIDP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Effect of Panzyga on modified Rankin Scale&#xD;
Measure of a patient's level of disability assessed on a scale of 0 (i.e., no symptoms) to 6 (death). Higher number associated with worse outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pediatric Chronic Inflammatory Demyelinating Polyneuropathy</condition>
  <arm_group>
    <arm_group_label>Panzyga High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Panzyga Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panzyga</intervention_name>
    <description>Intravenous immunoglobulin formulation</description>
    <arm_group_label>Panzyga High Dose</arm_group_label>
    <arm_group_label>Panzyga Low Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥2 years and ≤17 years.&#xD;
&#xD;
          2. Patients with a diagnosis of definite or probable CIDP based on European Neuromuscular&#xD;
             Center (ENMC) criteria.&#xD;
&#xD;
          3. Clinical history of functional impairment due to CIDP, corresponding to an mRS score&#xD;
             ≥2, but ≤5.&#xD;
&#xD;
          4. Voluntarily given written informed consent (provided by patient's parent or legal&#xD;
             guardian) or assent (provided by patient, if age-appropriate per Independent Ethics&#xD;
             Committee [IEC]/Institutional Research Board [IRB] requirements).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with previously diagnosed CIDP who lack any CIDP symptoms.&#xD;
&#xD;
          2. Patients with a known history of inherited neuropathy or a family history of inherited&#xD;
             neuropathy.&#xD;
&#xD;
          3. Patients who have previously failed immunoglobulin therapy for CIDP.&#xD;
&#xD;
          4. Patients who received immunoglobulin within 8 weeks prior to the Baseline visit&#xD;
             (washout phase). However, if a patient has clinical evidence of confirmed CIDP relapse&#xD;
             during the washout phase (consistent with an increase in mRS of ≥1), they are eligible&#xD;
             for trial enrolment.&#xD;
&#xD;
          5. Patients with a history of deep vein thrombosis (DVT) in the past year, or pulmonary&#xD;
             embolism ever.&#xD;
&#xD;
          6. Patients on unstable (change in prescribed dose within the last 8 weeks)&#xD;
             corticosteroids or rituximab use.&#xD;
&#xD;
          7. Patients with known or suspected hypersensitivity, anaphylaxis or severe systemic&#xD;
             response to immune-globulins, blood or plasma derived products, or any component of&#xD;
             PANZYGA.&#xD;
&#xD;
          8. Female patients who are breastfeeding, pregnant, or planning to become pregnant, or&#xD;
             are unwilling to use an effective birth control method while on the study (acceptable&#xD;
             methods of birth control for this study include: intrauterine device [IUD], hormonal&#xD;
             contraception, male or female condom, spermicide gel, diaphragm, sponge, or cervical&#xD;
             cap).&#xD;
&#xD;
          9. Known human immunodeficiency virus (HIV), hepatitis B virus (HBV), and/or hepatitis C&#xD;
             virus (HCV) infections.&#xD;
&#xD;
         10. Severe liver and/or kidney disease (alanine aminotransferase [ALT] &gt; 3 × upper limit&#xD;
             of normal [ULN]; aspartate aminotransferase [AST] &gt; 3 × ULN; and/or creatinine levels&#xD;
             &gt;44 μmol/L for children ages 2-3 years, &gt;62 μmol/L for children ages 4-10, and &gt;89&#xD;
             μmol/L for children ages 11-17 years.&#xD;
&#xD;
         11. Known immunoglobulin (IgA) deficiency and antibodies against IgA.&#xD;
&#xD;
         12. History of alcohol or drug abuse in the previous year, as per Investigator's opin-ion.&#xD;
&#xD;
         13. Unable or unwilling to comply with the study protocol.&#xD;
&#xD;
         14. Receipt of any other investigational medicinal product (IMP) within 3 months be-fore&#xD;
             study entry.&#xD;
&#xD;
         15. Any other condition(s) that, in the Investigator's opinion, makes it undesirable for&#xD;
             the patient to participate in the study or may interfere with protocol compliance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mikaela Raymond</last_name>
    <phone>866-337-1868</phone>
    <email>ctgov@clinicalresearchmgt.com</email>
  </overall_contact>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 11, 2021</study_first_submitted>
  <study_first_submitted_qc>June 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2021</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyneuropathies</mesh_term>
    <mesh_term>Polyradiculoneuropathy, Chronic Inflammatory Demyelinating</mesh_term>
    <mesh_term>Polyradiculoneuropathy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

